1. Home
  2. PSN vs MIRM Comparison

PSN vs MIRM Comparison

Compare PSN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parsons Corporation

PSN

Parsons Corporation

HOLD

Current Price

$56.52

Market Cap

6.3B

Sector

Technology

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$99.61

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSN
MIRM
Founded
1944
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.7B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
PSN
MIRM
Price
$56.52
$99.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
13
Target Price
$79.18
$119.85
AVG Volume (30 Days)
1.1M
599.7K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
3.77
74.59
EPS
0.49
N/A
Revenue
$6,364,245,000.00
$19,138,000.00
Revenue This Year
$5.87
$26.22
Revenue Next Year
$7.61
$22.04
P/E Ratio
$115.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$48.23
$47.89
52 Week High
$89.50
$114.99

Technical Indicators

Market Signals
Indicator
PSN
MIRM
Relative Strength Index (RSI) 51.29 53.73
Support Level $48.81 $95.68
Resistance Level $59.00 $107.51
Average True Range (ATR) 2.50 4.25
MACD -0.20 0.20
Stochastic Oscillator 40.69 77.87

Price Performance

Historical Comparison
PSN
MIRM

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: